Skip to main content

Moleculin Biotech, Inc 10-Q for FY2026 Q3

Moleculin Biotech, Inc. (MBRX)

10-Q 2026-11-13 For: 2026-09-30
View Original
Added on November 14, 2026

About this 10-Q

Moleculin Biotech, Inc filed this 10-Q on November 13, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Moleculin closed MIRACLE Part A enrollment at 90 subjects; data are expected in the first quarter of 2027, after interim complete remission rates of 43% and 36% in two Annamycin arms versus 12% for control. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$0
compared with $0 a year earlier
Net loss
$6.49M
compared with a net loss of $25.4M a year earlier